A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

被引:1
|
作者
Assaf, Chalid [1 ,2 ]
Illidge, Timothy M. [3 ]
Waser, Nathalie [4 ]
He, Mary [4 ]
Li, Tina [4 ]
Zomas, Athanasios [5 ]
Bent-Ennakhil, Nawal [5 ]
Little, Meredith [6 ,10 ]
Ortiz-Romero, Pablo L. [7 ]
Pimpinelli, Nicola [8 ]
Dalal, Mehul [6 ]
Bagot, Martine [9 ]
机构
[1] Helios Klinikum Krefeld, Dept Dermatol, Lutherpl 40, D-47805 Krefeld, Germany
[2] Med Sch Hamburg, Inst Mol Med, D-20457 Hamburg, Germany
[3] Univ Manchester, Christie Hosp, Manchester NIHR BRC Ctr, Manchester M20 4BX, England
[4] ICON Plc, 3455 North Serv Rd,Unit 400, Burlington, ON L7N 3G2, Canada
[5] Takeda Pharmaceut Int AG, Thurgauerstr 130, CH-8152 Zurich, Switzerland
[6] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA 02421 USA
[7] Univ Complutense, Hosp Octubre 12, Inst I 12, Med Sch,Dept Dermatol,CIBERONC, Madrid 28041, Spain
[8] Univ Florence, Hosp P Palagi, Med Sch, Sect Dermatol,Dept Hlth Sci, Viale Michelangiolo 41, I-50125 Florence, Italy
[9] Univ Paris Cite, St Louis Hosp, 1 Ave Claude Vellefaux, F-75010 Paris, France
[10] Agios Pharmaceut, Cambridge, MA 02129 USA
关键词
mycosis fungoides; relapsed/refractory; treatment patterns; Europe; real-world data; observational study; overall survival; progression-free survival; HEMATOPOIETIC-CELL TRANSPLANTATION; EORTC CONSENSUS RECOMMENDATIONS; PRIMARY CUTANEOUS LYMPHOMAS; SEZARY-SYNDROME; INTERNATIONAL-SOCIETY; BRENTUXIMAB VEDOTIN; ORGANIZATION; GUIDELINES; DIAGNOSIS;
D O I
10.3390/cancers15235669
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Here, we report real-world treatment patterns and the overall survival of 104 patients with relapsing/refractory (R/R) MF who had received first-line therapy between 1984 and 2016. Our study found that second- and third-line therapies for R/RMF were heterogeneous, including systemic therapies, radiotherapy and topical therapies. More than two-thirds of patients at second- and third-line treatment received chemotherapy, and we observed that the median overall survival was longer with non-chemotherapy (not reached) vs. chemotherapy (6.5 years) treatment, suggesting that non-chemotherapy options may be more beneficial to patients.Abstract (1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lymphoma (CTCL), develop relapsed/refractory (R/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes from the subpopulation with R/R MF. (2) Methods: This observational, retrospective, cohort study analyzed patient records (1984-2016) from 27 clinical sites in Europe. Outcomes included treatments received, response to first-, second- and third-line treatment, overall survival (OS) and progression-free survival (PFS). (3) Results: Of 104 patients with MF, 100 received second-line and 61 received third-line therapy. The median (range) times from the start of first-line therapy to the first R/R MF and from the first to the second R/R MF were 11.2 (0.3-166.5) and 13.5 (0.0-174.6) months, respectively. Second-and third-line treatment options varied and comprised systemic therapies (85% and 79% of patients, respectively), radiotherapy (32% and 34%, respectively) and topical therapies (48% and 36%, respectively). The median (95% confidence interval [CI]) OS from the diagnosis of the first R/R MF was 11.5 (6.5-not reached [NR]) years and was higher with non-chemotherapy (NR) versus chemotherapy (6.5 years); the estimated median PFS (95% CI) from the time of the first R/R MF was 1.3 (1.0-2.1) years. (4) Conclusions: High rates of R/R disease were observed after second- and third-line treatments in this real-world cohort, with longer median OS in patients receiving non-chemotherapy treatment versus chemotherapy. Following the standard management of MF and using recently approved targeted therapies can help improve patient outcomes in advanced-stage MF.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study
    Andrew Maguire
    Beth D Mitchell
    Javier Cid Ruzafa
    BMC Endocrine Disorders, 14
  • [42] Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)
    Johnston, K.
    Levy, A. R.
    Lorigan, P.
    Maio, M.
    Lebbe, C.
    Middleton, M.
    Testori, A.
    Bedane, C.
    Konto, C.
    Dueymes, A.
    Sbarigia, U.
    van Baardewijk, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (14) : 2175 - 2182
  • [43] HOSPITALISATIONS AMONG ADULT PATIENTS WITH PH-NEGATIVE B-PRECURSOR RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) RECEIVING CHEMOTHERAPY IN GERMANY: A RETROSPECTIVE CHART REVIEW
    Kreuzer, K.
    Stuhlmann, R.
    Lebioda, A.
    Reitan, J.
    Barber, B. L.
    Barlev, A.
    VALUE IN HEALTH, 2015, 18 (07) : A443 - A443
  • [44] Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study
    Sharman, Jeff
    Kabadi, Shaum M.
    Clark, Jamyia
    Andorsky, David
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (04) : 737 - 746
  • [45] A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments
    Michael J Wagner
    Leo Ismaila Amodu
    Mei Sheng Duh
    Caroline Korves
    Franco Solleza
    Stephanie C Manson
    José Diaz
    Maureen P Neary
    George D Demetri
    BMC Cancer, 15
  • [46] A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments
    Wagner, Michael J.
    Amodu, Leo Ismaila
    Duh, Mei Sheng
    Korves, Caroline
    Solleza, Franco
    Manson, Stephanie C.
    Diaz, Jose
    Neary, Maureen P.
    Demetri, George D.
    BMC CANCER, 2015, 15
  • [47] Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the United Kingdom, Germany, France, Spain, and Italy (EU-5): Results from a physician survey
    DeKoven, Mitch
    Bonthapally, Vijayveer
    Lee, Won Chan
    Pathak, Prathamesh
    Jiao, Xiaolong
    Ray, Saurabh
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Criteria used to determine platinum eligibility and first-line (1L) treatment (tx) patterns among platinum-eligible (PE) and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in France, Germany, Spain, Italy, and the United Kingdom (Eu5).
    Milloy, Neil
    Kirker, Melissa
    Berry, Mia
    Kostikas, Michael
    Montgomery, Rachel
    Kearney, Mairead
    Costa, Nuno Matos
    Chang, Jane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [49] Treatment patterns and outcomes among patients with microsatellite stable (MSS) advanced endometrial cancer in the United States: Endometrial Cancer Health Outcomes (ECHO) retrospective chart review Study.
    Corman, Shelby
    Kelkar, Sneha
    Odak, Shardul
    Zhang, Jingchuan
    Prabhu, Vimalanand S.
    Rusibamayila, Nifasha
    Macahilig, Cynthia
    Duska, Linda R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331
    Garcia-Sanz, Ramon
    Balari, Anna Sureda
    Domenech, Eva Domingo
    Huelva, Francisco Javier Capote
    Gutierrez, Antonio
    Izquierdo, Antonia Rodriguez
    De Domingo, Marta Grande
    Baeza, Lourdes
    BLOOD, 2024, 144 : 2376 - 2377